00:40 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

UV-4B: Ph Ib started

Emergent began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate ascending doses of UV-4B oral solution thrice daily for 7 days in about 40 healthy volunteers. The company is developing UV-4B under a 5-year...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Company News

Migenix infectious, dermatology news

Migenix restructured and reduced headcount by 34 (18%) to 28 to enable the company to operate into 2009. The cuts were mostly in the R&D division. The company also reduced the number of directors from...
08:00 , Feb 4, 2008 |  BC Week In Review  |  Clinical News

Celgosivir: Expand Phase II

Migenix plans to increase enrollment in order to include a 600 mg celgosivir arm in an ongoing 12-week, Canadian Phase II trial that was evaluating peginterferon alfa-2b and ribavirin with or without 400 mg celgosivir...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

Celgosivir: Interim Phase II data

Interim 4-week data from a Phase II trial in 10 treatment-naïve patients showed that the median reduction in HCV RNA at 4 weeks was 3.5 log10 for celgosivir plus peginterferon alfa-2b and ribavirin vs. 3.8...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Clinical News

Celgosivir: Additional Phase II data

Re-analyzed data from an open-label Phase II trial in 57 patients showed that celgosivir plus pegylated peginterferon alfa-2b and ribavirin produced an early viral response (EVR) in 42% of patients who were non-responders to prior...
07:00 , Apr 9, 2007 |  BioCentury  |  Tools & Techniques

Ins & outs of HCV

In a pair of studies, researchers have identified two potential therapeutic targets for hepatitis C virus. Both are related to host cells, which means they might raise fewer viral resistance issues, although experience with similar...
08:00 , Jan 15, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 1/12 cls Genentech (DNA) Rodman Michael King Price target Market outperform 4% $86.83 Stifel, Nicolaus Edward Nash Price target Buy...
08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Celgosivir: Phase II data

In an open-label Phase II trial in 57 patients, celgosivir plus pegylated peginterferon alfa-2b and ribavirin was safe and well tolerated. The trial included 36 non-responders and 21 partial responders to previous pegylated interferon plus...
08:00 , Nov 6, 2006 |  BioCentury  |  Regulation

HCV antivirals

HCV antivirals HCV antivirals Selected HCV antiviral agents in clinical development. (A) Plans to start a Phase IIb program to test Viramidine at higher doses after mixed results were seen in two Phase III trials;...
07:00 , Jul 24, 2006 |  BC Week In Review  |  Clinical News

Celgosivir: Phase II start

This month, MGI will start a Canadian Phase II trial in up to 20 treatment-naïve HCV patients. The trial will compare celgosivir plus peginterferon alfa-2b and ribavirin with peginterferon alfa-2b and ribavirin. Migenix Inc. (TSX:MGI;...